内容概要：医药终端指的是药品被消费者购买的市场。医药工业是关系国计民生和国家安全的重要产 业。我国是世界工业医药大国，产业链完整，医药产品品种数量、生产能力位居全球前列。近年来，我 国医药工业高质量发展成效显著，医药终端是药品流通的最终交付环节在中国医药市场的广阔天地中， 长久以来，第一终端（公立医院）与第二终端（零售药店）一直占据着舞台的中心。中国药品终端市场 近年来总体保持稳定增长，但增速有所放缓。2025年前三季度，我国医药三大终端六大市场药品销售总 额达到13924亿元，其中，对公立医院终端药品销售额8290亿元，占终端销售额的59.5%；对零售药店 终端药品销售额4385亿元，占终端销售额的31.5%；对公立基层医疗终端药品销售额1249亿元，占终端 销售额的9.0%。 上市企业：益丰药房[603939]、一心堂[002727]、大参林[603233]、老百姓[603883]、漱玉平民 [301017]、健之佳[605266]、达嘉维康 [301126]、华人健康[301408] 2018-2025年前三季度中国医药三大终端六大市场药品销售总额 在中国医药市场的广阔天地中，长久以来，第一终端（公立医 ...

为进一步扩大非遗影响力，彭清东调研后建议，在长沙洋湖水街打造省级非物质文化遗产及老字号示范 展示街区，通过"常驻展示+市州轮展"模式，带动全省非遗项目走向更广市场，助力乡村振兴与乡亲增 收。 ■三湘都市报全媒体记者 罗艾敏 【人物档案】 "当代表，就是要多调研，把老百姓的心里话带上会场。"彭清东深知偏远山村民生之难：老人看病不 便、道路狭窄泥泞、饮水环境待改善。他坚持走村串户听取民意，自费带队考察，把百姓的"小事"当作 履职"大事"。经他多方推动，村道得以拓宽，自来水入户全覆盖，卫生厕所普及，村级卫生室持续优 化，村民生活品质显著提升。 民生改善后，彭清东将重心转向富民产业。他聚焦土家织锦"西兰卡普"这一非遗技艺，创办企业推动产 品研发与市场拓展，让传统手艺成为留守妇女的"致富锦"。 彭清东，省人大代表。 冬日的龙山县洗车河镇克洞村，水泥路蜿蜒连通家家户户，路灯点亮村道；土家织锦工坊内，彩线在织 娘们手中翻飞，一幅幅精美的"西兰卡普"正徐徐成型……这些民生改善、产业兴旺的画面，是省人大代 表彭清东扎根乡村数十年的履职答卷。 ...

Core Viewpoint - The Chinese real estate market is experiencing a long-term adjustment, with average national housing prices dropping over 30%, and certain cities seeing declines exceeding 60% [1][3]. Group 1: Trends in the Real Estate Market - Trend 1: Housing prices are beginning to show differentiation across regions, with second and third-tier cities experiencing a slowdown in price declines, while first-tier cities are likely to face a correction [5][3]. - Trend 2: A dual-track system in real estate is expected to emerge, allowing low-income families to apply for affordable housing while middle and high-income families can opt for purchasing such properties [7][3]. - Trend 3: The construction of quality housing is anticipated to become mainstream, as buyer expectations rise and government encourages developers to focus on quality [9][3]. - Trend 4: The proportion of existing home sales is projected to increase, allowing buyers to inspect properties before purchase, thereby reducing the incidence of unfinished buildings [11][3]. Group 2: Future Market Outlook - By 2026, housing prices are likely to continue a trend of "steady decline," with the expectation that housing market bubbles will be eliminated, prompting consumers to prepare for a significant market shift [11][3].

Core Viewpoint - The A-share pharmaceutical retail sector is experiencing a significant rebound, driven by a new policy aimed at promoting high-quality development in the industry, which is expected to help around 700,000 pharmacies currently facing challenges [2][3]. Group 1: Industry Trends - The pharmaceutical retail industry is undergoing a wave of closures, with a projected net closure of 39,000 stores in 2024, significantly higher than the 3.8% closure rate in 2023 [5][6]. - The market is witnessing a shift from passive closures to proactive consolidation, as the new policy addresses industry pain points and encourages mergers and acquisitions [2][3][9]. - The concentration of the market is increasing, with the top 10 companies expected to reach a market share of over 35% by 2026, moving towards the levels seen in mature markets [9]. Group 2: Financial Performance - Major players in the industry are facing declining revenues and profits, with companies like YaoYao and GuoDa Pharmacy reporting significant drops in net profits, highlighting the financial strain on the sector [4][5]. - Only one out of six major private listed chains, Yifeng Pharmacy, is expected to achieve positive net profit growth in 2024, indicating a narrowing profitability landscape [5][6]. Group 3: Policy Impact - The new policy aims to standardize and optimize the merger and acquisition process, reducing costs and time for major chains, thus facilitating industry consolidation [7][9]. - The policy encourages a shift from a focus on drug sales to a broader health service model, aligning with changing consumer demands and promoting diversification in product offerings [8][9]. Group 4: Future Outlook - The industry is expected to evolve from merely selling drugs to becoming comprehensive health service providers, enhancing efficiency and better meeting consumer needs [10][11]. - The ongoing transformation is anticipated to eliminate inefficient capacities and elevate industry standards, marking a transition to a new phase of value growth [11].

Group 1 - The "Implementation Plan for Strengthening the Foundation in Disease Prevention and Control" aims to enhance the grassroots disease control system by addressing issues such as resource imbalance, outdated equipment, and weak digital capabilities [1][2] - The plan sets two key targets: by the end of 2027, a basic grassroots disease control network will be established, and by 2030, the system will be optimized for efficiency and digital empowerment [1][2] Group 2 - Companies in the industry are actively aligning their strategies with the policy requirements, focusing on technology development, product offerings, and practical applications [3] - Shengxiang Biotechnology Co., Ltd. is developing integrated solutions that include rapid testing reagents, devices, and digital systems to meet the core needs outlined in the policy [3] - Retail pharmacies, such as Lao Baixing Pharmacy Chain Co., Ltd., play a crucial role in disease control by providing essential services and medication supply, thus enhancing public health service capabilities [4] - Kefu Medical Technology Co., Ltd. is focusing on smart upgrades of its products to provide efficient diagnostic and health management tools for grassroots healthcare facilities [4]

Market Overview - The pharmaceutical commercial sector declined by 1.0% on January 28, with Renmin Tongtai leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] Stock Performance - Notable gainers in the pharmaceutical sector included: - China Medicine (600056) with a closing price of 11.21, up 2.28% and a trading volume of 531,600 shares, totaling 593 million yuan [1] - Yixin Pharmacy (002727) closed at 14.09, up 0.64% with a trading volume of 220,100 shares, totaling 311 million yuan [1] - Major decliners included: - Renmin Tongtai (600829) closed at 12.35, down 4.93% with a trading volume of 432,700 shares, totaling 537 million yuan [2] - Saili Medical (603716) closed at 23.29, down 4.71% with a trading volume of 157,600 shares, totaling 374 million yuan [2] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 528 million yuan from institutional investors, while retail investors saw a net inflow of 603 million yuan [2] - The capital flow for key stocks showed: - China Medicine had a net inflow of 32.15 million yuan from institutional investors, but a net outflow of 15.57 million yuan from retail investors [3] - Shanghai Pharmaceutical (601607) had a net inflow of 9.01 million yuan from institutional investors, with a significant net outflow of 32.51 million yuan from retail investors [3]

【文/王力 编辑/周远方】 在效率至上、利润优先的商业世界里，一个根本性问题常被搁置：基于严谨科学、能真实改善生活的产品，其价值是否必然与高昂价格绑定？2026年初，于 河北金山岭长城脚下，上海家化旗下医学护肤品牌玉泽，用其23年的历程给出了坚定而温暖的答案。 这一答案的源头，需回溯至23年前。上海家化与瑞金医院皮肤科开启了一项看似"反效率"的合作。历经六年研发与上千例临床验证后，在定价的关键时刻， 上海交通大学医学院附属瑞金医院终身教授、玉泽首席科学家郑捷基于临床中对皮肤患者真实处境的深刻理解，坚决主张：医学护肤应服务于真正的皮肤健 康需求，是"雪中送炭"，而非"锦上添花"。也正是这一坚定选择，为品牌奠定了坚实的价值根基——产品的意义，不止于功效，更在于被真正需要的人所信 赖与使用。 而今最初的承诺已生长为坚实的体系。通过设立专项慈善基金形成"公益+科研"闭环，累计完成超5000例临床研究，并与全国40余家顶尖医院持续合作，玉 泽构筑起一道独特的"医研长城"。从最新推出的特润霜，到同步发布的《国民皮肤屏障健康绿宝书》，玉泽始终在践行同一个使命：让基于实证的医学护 肤，真正从实验室走向千家万户百姓，守护千万人 ...

[Table_Reportdate] 2026年01月27日 [证券分析师： Table_Authors] 张季恺 S0630521110001 zjk@longone.com.cn 证券分析师： 王洋 S0630513040002 wangyang@longone.com.cn 联系人： 陈伟业 cwy@longone.com.cn 联系人： 邓尧天 dytian@longone.com.cn [晨会纪要 Table_NewTitle] 20260127 重点推荐 财经要闻 晨 会 纪 要 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 [table_summary] ➢ 1.药品零售新政出台，赋能行业高质量发展——医药生物行业周报（2026/01/19- 2026/01/25） ➢ 2.2026年全球AI服务器出货同比有望增超28%，AI相关芯片涨价持续——电子行业周报 2026/1/19-2025/1/25 ➢ 1.商务部：将优化实施消费品以旧换新，促进家电等大宗耐用商品消费 ➢ 2.上期所调整白银、锡期货相关合约交易限额 ➢ 3.香港特别行政区行 ...

Core Insights - The beauty industry is witnessing a shift as leading brands are refocusing on offline channels, which are expected to become a significant growth area by 2026 [1][3] - Major companies like Marubi, Proya, and Shiseido are signaling a strategic pivot towards offline sales, indicating a collective recognition of the potential profitability in this space [1][3][4] Group 1: Market Trends - The past year has seen brands expressing concerns over high competition, expensive traffic, and declining online sales, leading to a reevaluation of growth strategies [1][2] - Data from 2023-2024 shows slight increases in offline revenues for major brands, but their overall contribution to total revenue is declining, highlighting a need for strategic investment in offline channels [3][4] Group 2: Strategic Shifts - Natural堂 has demonstrated the potential of offline channels, with average annual revenues exceeding 1.6 billion yuan over the past three years, indicating that offline can still be a vital growth area [4] - The increasing costs of online traffic and the saturation of online platforms are pushing beauty brands to reconsider their channel strategies, making offline channels a more attractive option for sustainable growth [4][5] Group 3: OTC Channel Opportunities - The OTC (Over-the-Counter) channel is emerging as a key battleground for domestic brands, with over 30% of the top 100 cosmetic brands already having products displayed in pharmacies [6][7] - Major pharmacy chains are actively seeking to expand their beauty product offerings, with plans to introduce personal care items in a significant number of their stores [6][7] Group 4: Brand Strategies - Brands are adopting targeted product strategies for different channels, with Marubi launching new products specifically for offline sales and Proya entering the OTC market with a focus on medical and cosmetic synergy [8][9] - The emphasis is on creating engaging in-store experiences and building emotional connections with consumers to enhance brand loyalty and drive sales [10][11]

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry is expected to outperform the broader market index (CSI 300) by at least 10% over the next six months [1]. Core Insights - The pharmaceutical and biotechnology sector experienced a slight decline of 0.39% during the week of January 19-23, 2026, ranking 27th among 31 sectors, while outperforming the CSI 300 index by 0.23 percentage points. The current PE valuation for the sector stands at 30.27 times, which is at the historical median level, with a valuation premium of 126% compared to the CSI 300 [5][16][23]. - The top-performing sub-sectors during this period were pharmaceutical commerce (4.26%), traditional Chinese medicine II (0.89%), and medical devices (0.30%) [5][14]. - A total of 330 stocks (69.62%) in the sector rose, while 137 stocks (28.90%) fell. The top five gainers included *ST Changyao (70.37%), Hualan Biological Engineering (32.21%), and Kangzhong Medical (25.47%) [5][31]. Market Performance - The pharmaceutical and biotechnology sector's performance for the year-to-date shows an increase of 6.66%, ranking 16th among 31 sectors and outperforming the CSI 300 index by 5.10 percentage points. The sub-sectors that achieved growth included medical services (13.53%), medical devices (9.50%), and pharmaceutical commerce (7.77%) [16][22]. - The PE valuations for various sub-sectors are as follows: medical devices (36.13), chemical pharmaceuticals (34.34), biological products (33.61), medical services (32.89), traditional Chinese medicine II (22.22), and pharmaceutical commerce (17.16) [23][30]. Industry News - On January 22, 2026, nine government departments, including the Ministry of Commerce and the National Health Commission, jointly issued guidelines aimed at promoting high-quality development in the pharmaceutical retail industry. The policy focuses on six key areas, emphasizing a combination of government guidance and market leadership to enhance professional and intensive development within the industry [6][33]. - The guidelines encourage the integration of pharmaceutical services, improvement of pharmacy service capabilities, and the promotion of prescription circulation and medical insurance outpatient coordination services. They also support the establishment of a commercial insurance payment system and the expansion of health management services [6][33][34]. Investment Recommendations - The report suggests a cautious approach to the pharmaceutical and biotechnology sector, highlighting the recent weak performance of previously popular stocks. It emphasizes the importance of the new guidelines in transforming the industry from a "single drug sales" model to a "health service" model [6][34]. - The report recommends focusing on leading chain pharmacies with strong financial capabilities and merger integration abilities, as well as innovative drug chains, medical devices, healthcare services, and second-class vaccines for potential investment opportunities [6][34][7].